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Abstract 
 
 Studies have demonstrated an association between loss of heterozygosity on 
chromosome 1p and chromosome 19q in oligodendrogliomas with both chemosensitivity 
and prolonged survival.  This represents the first time genetic mutations have been 
utilized to guide clinical decision making.  Studies have also found these genetic 
mutations to be associated with magnetic resonance imaging (MRI) features including 
indistinct tumor borders on T1-weighted imaging, susceptibility effect, and mixed signal 
intensity.  However, no study has yet demonstrated an association between imaging 
features and survival.  We seek to confirm the clinical utility of known prognostic factors 
such as age and tumor grade while investigating the potential importance of imaging 
characteristics in predicting survival. 
 We conducted a large, single-institution retrospective chart review of patients 
with tissue diagnoses of oligodendroglioma.  Pathology reports, allelic status studies, MR 
imaging, and survival information were reviewed.  Survival curves, Two-sided chi-square 
tests, and generalized linear models failed to reveal an association between survival and 
gender, age, tumor grade, allelic status, or imaging characteristics.  We found no 
association between imaging characteristics and allelic status.  The failure to confirm 
even well-accepted prognostic factors suggests limitations in the study largely 
attributable to small sample size.  This limitation was due to availability of necessary 
information, rarity of the tumor, and only recent availability of genetic testing.  Further 
studies with larger populations need to be conducted to fully determine the prognostic 
utility of MRI features. 
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Introduction 
Epidemiology and Clinical characteristics.   
 Primary brain tumors are traditionally subdivided into tumors of neuroepithelial 
tissue composed predominantly of gliomas, tumors of the meninges, germ cell tumors, 
tumors of the sellar region, lymphoma, and hemopoietic neoplasms (See Table A).1  
 Gliomas, including astrocytomas, oligodendrogliomas, and ependymomas, 
comprise 70% of primary brain tumors with an incidence of 5.27/100,000 persons.2  
Incidence rates have been similar in recent population-based studies with the Central 
Brain Tumor Registry of the United States reporting rates of primary brain tumors where 
oligodendrogliomas represented 2.7%, anaplastic oligodendrogliomas 1.3%, and 
oligoastrocytomas 1.1%.  Trends reveal an increasing incidence of these tumors although 
this is difficult to determine with changing histopathologic criteria and increasing use of 
MR imagining.3, 4 
Oligodendrogliomas are currently defined by the World Health Organization 
(WHO) as “well-differentiated, diffusely infiltrating tumors of adults that are typically 
located in the cerebral hemispheres and composed predominantly of cells 
morphologically resembling oligodendroglia.”1  While the exact wording of this 
definition has changed, the basic classification and grading of these tumors has changed 
little since the 1993 WHO classifications.1  Oligodendrogliomas are classified as either 
oligodendrogliomas (WHO Grade II) or anaplastic oligodendrogliomas (WHO Grade III).  
While anaplastic tumors are technically defined as having “focal or diffuse histological 
features of malignancy and a less favorable prognosis,” they are histologically defined by 
 2
 
the presence of increased cellularity, increased mitotic activity, marked atypia, 
microvascular proliferation, and necrosis.1 
Oligodendrogliomas can develop anywhere in the neuroaxis where 
oligodendrocytes are located.  Ninety percent of these tumors are supratentorial, 
predominantly in the frontal and frontotemporal cortex.4, 5  Tumors are commonly found 
in the frontal (55%), temporal (47%), parietal (20%), and occipital (4%) lobes.6  This 
distribution is age dependent, however, as supratentorial oligodendrogliomas are not 
observed in children.  In patients under the age of 18 years, 67% of oligodendrogliomas 
occur in the cerebellum.2  Interestingly, the tumor’s location correlates with the presence 
of specific genetic mutations to be discussed later.7  Oligodendrogliomas have a 
predilection for subcortical white matter with extension to the cortex.8  Their pattern of 
spread can result in tumor extension through the corpus callosum, across the ependyma, 
into deeper brainstem structures and even into the leptomeninges inducing a desmoplastic 
reaction.8, 9   
Gliomas present at slightly different ages with oligodendrogliomas WHO grade II 
presenting at 40.9 + 15.1 years, anaplastic oligodendrogliomas at 50.4 + 13.9 years, 
anaplastic oligoastrocytoma at 48.2 + 17.4 years and glioblastoma at 62.2 + 13.4 years.2  
Oligodendrogliomas have a bimodal age distribution with the first peak from 6-12 years 
and then a second peak from 26-46 years.4  However, only 7.5% of oligodendrogliomas 
are diagnosed in children.4  There is a slightly gender dimorphic distribution of disease 
with a male-to-female ratio ranging from 1.2 to 3.0.6  The age of presentation peaks 
differently according to gender with males peaking at 45-49 years and women peaking at 
55-59 years.10 Clinical symptoms at presentation are similar to other intracranial tumors 
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including seizures and symptoms of increased intracranial pressure such as headache, 
visual changes, paralysis, vomiting, papilledema, ataxia, and mental status change.4, 6, 11  
No single symptom has been found to correlate with tumor grade.6  The median duration 
of symptoms before diagnosis has been described as 20.5 months (mean 43 months)12 but 
can range from 2.9 months to 16 years.4, 6 
Pathology 
The pathogenesis of oligodendrogliomas remains elusive.  Candidate progenitor 
cells include dedifferentiated mature cells or glial progenitor cells. While stem cell-like 
cells have been isolated from glial tumors, neoplastic cells have such marked genetic 
hetrogenicity and epigenic alterations that the critical event in tumor development has not 
been determined.3 
Macroscopically, oligodendrogliomas are well defined masses of “fleshy to 
pinkish-gray color” with a soft, gelatinous texture. They may have a gritty texture due to 
microcalcifications.  Hypervascularity may be noted but edema is uncommon.  Grossly 
cystic necrosis is only present in malignant forms although zones of cystic degeneration 
can be detected in more benign tumors.  Due to their tendency to invade the cortex, 
oligodendrogliomas may obliterate the gray-white junction and focal areas of 
leptomeningeal infiltration may be present. 8, 9  In some cases, this infiltration can 
produce a desmoplastic reaction that resembles metastatic carcinoma.9 
Microscopic examination of oligodendrogliomas reveals uniform, round nuclei 
with clear cytoplasm.  The presence of oligodendroglia suggests an oligdendroglioma, 
astrocytoma, or mixed glioma.  Fibrillary astocytoma is an infiltrative astocytoma that 
most closely resembles oligodendroglioma however exhibits irregular, elongated, 
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hyperchromatic nuclei that differ from the appearance of oligodendrogliomas.13  The 
distinction between these can be challenging due to interobserver and intratumor 
variability.  However, this differentiation is an important one as patients with 
astrocytomas or mixed gliomas have a shorter life expectancy than patients with 
oligodendrogliomas.14-17  Another entity that closely resembles oligodendroglioma is 
dysembryoplastic neuroepithelial tumor (DNT).  DNTs are extremely slow growing, 
superficial neoplasms found during the first decades of life that presents with long-
standing seizures.5 
Cellular characteristics of oligodendrogliomas are best appreciated on tissue 
smears.  With this preparation, samples appear moderately cellular with individual cells 
being uniformly round with homogeneous nuclei, swollen clear cytoplasm and a lack of 
cohesion.  Cells are typically enmeshed in a fibrillary, eosinophilic matrix and lack 
fibrillary processes however there is variability in the cell density and relationship with 
surrounding tissue.8, 9  A classification system has been proposed that classifies 
oligodendrogliomas according to these characteristics.  In this system 
oligodendrogliomas are classified into structure type II or structural type III.  Structural 
type II is defined by solid tumor tissue components and destruction of surrounding 
neurons.  Structural type III is defined by isolated tumor cells closely resembling 
oligodendroglia.  While this classification system is not universally accepted, it has been 
shown to correlate with biological behavior of tumors.18   
Tumor cells are particularly susceptible to processing which can result in 
characteristic perinuclear vacuolization.9  On formalin-fixed, paraffin embedded material, 
cells appear to have perinuclear halos that create the classic “fried-egg” appearance.  This 
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appearance is due to artifact but still represents a useful diagnostic feature.5, 8  Other 
microscopic characteristics include microcalcifications, mucoid/cystic degeneration,8 and 
intratumoral hemorrhage.5  Characteristic changes in vascularity include a “chicken-wire” 
appearance created by increased branching of local capillaries.8  Varying frequency of 
astrocytes within oligodendrogliomas causes challenges in determining if they represent 
reactive astrocytes within an invasive tumor, transitional forms of oligodendroglial cells, 
or independently neoplastic cells.8  Also present could be sub-populations of 
minigemistocytes 8 characterized by eccentric cytoplasm that is GFAP positive.  
Characteristics typical of anaplastic degeneration include increased nuclear size, 
hyperchromasia and pleomorphism.9  Focal necrosis and endothelial proliferation are also 
ominous changes. 
 Few immunohistochemical markers have proven helpful in confirming the 
diagnosis of oligodendroglioma.  Glial markers include GFAP, an intermediate filament, 
and S-100 protein.  Neither marker is specific for oligodendrogliomas.13  Other candidate 
markers have included overexpression of PDGF and its receptor,3 expression of 
galactocerebroside (GalC),9 elevated myelin basic protein,9 p53 positive cells,19, 20 
presence of Olig2,21 and expression of YLK-40 in the tissue and serum.22, 23   All of these 
have insufficient specificity to be routinely used in clinical practice. Oligodendrogliomas, 
more frequently than astrocytomas, overexpress a variety of genes including DES, 
TDGF1, TGF-β, GABA-BR1A, Histone H4, CDKN1A, PCDH43, Rho7 and Jun-D while 
underexpressing JNK2, ITGB4, JNK3A2, RgoC, IFI-56K, AAD14, and EGFR.24  
However, none of these markers have proven to be sufficiently sensitive or specific.  
Markers of cellular proliferation have been useful in prognosis but not diagnosis.  The 
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most frequently used marker is Ki-67, a nuclear protein that is expressed only when cells 
are in the M phase of the cell cycle13, 25 and can be marked with MIB-1 antibody.26  
Expression of TP53 and LOH at 17p are uncommon.24, 27 TP53 overexpression is noted in 
88% of gemistocytic astrocytomas, 53% fibrillary astrocytomas, and 44% of 
oligoastrocytomas but only 13% of pure oligodendrogliomas.2  Other genetic alterations 
have remained elusive with promising yet ultimately unrevealing characteristics 
including deletions on 4q, 9p, 13q, and 17p along with amplification of 7q, 8q, and 
11q.14, 28  Loss of heterozygosity (LOH), where one of two copies of a specific gene is 
lost, on chromosome 10 and gain of genes on chromosome 7 have been shown to be 
associated with glioblastoma multiforme but not oligodendroglioma.2, 28  Homozygous 
deletion or epigenetic silencing of CDKN2A/p14ARF, overexpression of EGFR, loss of 
RB1, and amplification of CDK4  have been shown to be useful with identifying 
anaplastic oligodendrogliomas 3,29 
Although immunohistochemistry has limited usefulness in differentiating 
oligodendrogliomas from other CNS malignancies, detecting LOH on chromosome 1p 
with or without LOH on chromosome 19q has revolutionized diagnosis, treatment 
decisions, and prognosis of these tumors. 8, 15, 27 Various genetic mutations harbored 
within neoplastic cells have been defined and subsequently used for diagnosis and 
therapy decisions. With two copies of each chromosome, loss or gain of genetic material 
on one or both copies can profoundly influence the behavior of that cell.  Loss of a tumor 
suppressor gene or gain of an oncogene has been associated with neoplastic growth.  
These two types of mutations are thought to be the underlying mechanism of 
tumorgenesis in these tumors.  With oligodendrogliomas, however, the link between 
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genetic mutation and phenotype remains elusive as the characteristic loss of one of the 
two copies of the short arm of chromosome 1 (1p) with or without the loss of the long 
arm on chromosome 19 (19q) lack known oncogenic mechanism.  These mutations are 
unique as it is not just a specific gene that is gained or lost but typically an entire arm of 
the chromosome leading to homozygosity.  
Various techniques are used in the detection of these mutations including loss of 
heterozygosity (LOH), quantitative polymerase chain reaction (PCR), and fluorescence in 
situ hybridization (FISH).30  Briefly, LOH testing is conducted by grossly detecting 
restricted fragment length on the chromosomes of interest.  As this technique requires 
large quantities of tumor and is very time-consuming it is rarely used today.30  PCR 
testing involves detecting the presence or absence of microsatellite gene sequences in 
tumor cells verses constitutional tissue (frequently peripheral lymphocytes) from the 
same patient.  If the chromosome of interest from the tumor cells has markers for only 
one set of microsattelite markers whereas the peripheral cells exhibit two copies, the 
sample is deemed LOH.30  Finally, FISH utilizes fluorescent markers of intranuclear 
signals reflecting a heterozygous state.  Thus, these signals are lost when genetic 
deletions are present.  Advantages of this technique include the ability to use paraffin-
embedded samples and not requiring constitutional tissue for comparison.  No standard 
means of detection has been established as the sensitivity and specificity of these tests 
have not yet been determined.  Thus, different studies utilize different techniques and are 
considered equivalent. 
Many studies have demonstrated the importance of 1p with or without 19q 
deletions (1p/19q LOH) in oligodendrogliomas.  The original study demonstrated that of 
 8
 
21 oligodendrogliomas, 81% had LOH on 19q and 67% had LOH on 1p.27  Subsequent 
studies with larger sample sizes have suggested the actual proportion is closer to LOH on 
1p occurring in 83% (40-92%), 19q in 66% (50-80%)8, and combined loss in 66% of 
oligodendrogliomas.31  Loss of 1p is highly associated with loss of 19q, together 
constituting the earliest known molecular change in 50-70% of oligodendrogliomas.32  
Only 20% of mixed tumors have LOH at 1p/19q and studies have shown the deletions to 
be significantly more common in oligodendrogliomas than astrocytomas31  LOH on 
1p/19q is also mutually exclusive to other markers found in intracranial tumors including 
TP53 overexpression, LOH on 17p,24, 27 LOH on 10, gain on 7.2, 28 Thus, the presence of 
any of these mutations makes the diagnosis of oligodendroglioma extremely unlikely.  
The presence of epigenetic silencing of CDKN2A/p14ARF, overexpression of EGFR, loss 
of RB1, and amplification of CDK4 would also make the diagnosis of oligodendroglioma 
extremely unlikely.29 
The significance of 1p/19q LOH in oligodendroglioms has raised questions 
regarding contents of the deleted genes, particularly as this deletion is seen in numerous 
other solid tumors.31  Many groups have attempted to identify a tumor suppressor gene on 
these chromosomes but a definitive gene has not been identified.3 One group determined 
that a deletion of 1p36 within the CAMTA1 gene to be present in all oligodendrogliomas 
with LOH on 1p.  This deletion is associated with reduced CAMTA1 expression by half 
suggesting it could represent a tumor suppressor gene.31  Another group identified a 
potential 19q locus to be 19q13.3 and have suggested P190RhoGAP, a protein known to 
be involved in oligodendrocyte differentiation located in that area, as a candidate gene.  
The suggested mechanism is that this deletion leads to decreased Rho activity thus 
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reducing PDGF levels and oncogenesis.33  However, other studies have demonstrated that 
PDGF levels are actually elevated in oligodendrogliomas making this explanation 
questionable. 
Imaging 
 The evolution of imaging intracranial tumors has changed profoundly over the 
previous 50 years.  Early articles on oligodendrogliomas noted frequent calcifications 
seen on cranial X-ray.12  Computer tomography provided a major advancement in 
determining tumor location and characteristics.  A CT finding that can suggest a mass is 
an oligodengroglioma is the presence of linear or nodular tumoral calcifications.  
Oligodendrogliomas have the highest frequency of calcification among intracranial 
tumors and such calcifications are reported in 50-90% of these tumors.5 
 The widespread availability and use of magnetic resonance imaging (MRI) has 
revolutionized the diagnosis, surgical management, radiation planning, chemotherapeutic 
evaluation, and monitoring of intracranial neoplasms.32  However, traditional criteria 
such as location in the neuroaxis and patient age are still relied upon in determining the 
most likely type of tumor prior to tissue diagnosis.  MRI provides unprecedented details 
of the characteristics of the tumor.  As discussed earlier, oligodendrogliomas tend to be 
found in patients in their fourth and fifth decades and located in the frontal lobes.  T1 
weighted imaging typically reveals a hypointense  mass unless paramagnetic effects from 
hemorrhage, necrosis, or calcification are present.5  Enhancement after administration of 
gadolinium-DTPA on T1 weighted imaging has been linked to more aggressive tumor 
behavior, however this observation remains controversial.4, 18, 34  T2 weighted imaging 
reveals a heterogeneous mass that may be isointense or hypterintense compared with gray 
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matter.  T2 imaging also reveals characteristic cortical thickening that can help 
distinguish the mass from astrocytic tumors which arise within the white matter. The 
distinction of a large intratumoral hemorrhage from a large intracranial hemorrhage in the 
absence of a structural lesion can be difficult, especially in the acute setting. Often repeat 
imaging is needed after an interval of 4-6 weeks.  Since most oligodendrogliomas are of 
low grade, typically, minimal edema is seen.  To better detect intratumoral calcification, 
gradient echo MR imaging can be performed as it is more sensitive to calcium products 
than is conventional spin echo MR imaging .5 
 A number of MRI characteristics have been statistically associated with LOH on 
1p/19q.  Tumors located in the frontal, parietal, or occipital lobe are likely to harbor these 
mutations while tumors of the temporal lobe, insula, and diencephalon are more likely to 
lack these genetic alterations.7  Tumors growing across the midline are also likely to have 
1p/19q LOH.7  Tumors that have LOH on 1p/19q are more likely to display indistinct 
borders on T1 pre-gadolinium images whereas those with intact chromosomes 1 and 19 
are more likely to have sharply demarcated borders.32  Additionally, oligodendrogliomas 
with LOH on 1p/19q are more likely to display mixed signal intensity on T1 and T2 and 
magnetic susceptibility change.32  Independent of genetic mutations, anaplastic tumors 
frequently have ring enhancement on post-gadolinium T1 weighted images. 
Positron emission tomography (PET) scans have proven a useful supplement to 
conventional MR imaging.  Tumors with LOH at 1p/19q display relatively increased 
metabolism of 18-fluorodeoxyglucose in PET.35  While PET scans are not in widespread 
clinical use, they have numerous potential uses including determining tumor type, degree 
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of malignancy, discriminating tumor vs. radiation necrosis, guiding biopsy, and assessing 
post-op tumor burden.4 
Therapy 
 Surgery remains the mainstay of treatment as it allows physicians to obtain tissue 
for diagnosis while reducing mass effect causing symptoms and neurological deficits.4  
The surgical goal is gross total removal4 as it has been shown to prolong survival.3  
However, it is currently impossible to determine extent of tumor infiltration into 
surrounding tissue and thus patients are rarely cured by surgery alone.4  Due to the 
inability to guarantee gross total resection most patients ultimately undergo both radiation 
and chemotherapy.  With low-grade tumors, adjuvant therapy is given at the time of 
radiographic progression or if clinical symptoms remain uncontrolled.  For anaplastic 
tumors, adjuvant therapy is usually administered at initial diagnosis.   
 The radiation field includes the area of T2 signal abnormality3 and has been 
shown to prolong survival, especially when gross total resection is not accomplished;4 
however the timing and effectiveness remains controversial.16, 36, 37  Response to RT has 
been associated with 1p/19q LOH.  Of patients who received radiation, those with 1p 
LOH have significantly longer survival such that WHO Grade II tumors with LOH on 1p 
having a mean progression-free survival of 55.0 months versus 6.2 months for those with 
retained heterozygosity.  For Grade III tumors, patients with LOH had progression free 
survival of 49.8 months versus 5.7 months in those with retained heterozygosity.  In fact, 
in that study LOH on 1p was of greater prognostic value than age or Karnofsky 
performance score.38 
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 The importance of determining if there is LOH at 1p/19q is best appreciated in the 
dramatic effect on chemosensitivity.  LOH on 1p has been strongly associated with 
radiographic response to chemotherapy and long survival times.15  In one study, all 
chemosensitive tumors harbored LOH on 1p while 89% of chemosensitive tumors had 
LOH on 1p.15  With this discovery, chemotherapy is now able to be used in a more 
selective fashion.  It is frequently used when radiotherapy would have exposed more that 
50% of the hemispheres.39  The current mainstay of therapy is the use of temozolomide or 
a combination of procarbazine, lomustine (CCNU), and vincristine (PCV) before and/or 
after radiotherapy.4  Prospective studies investigating efficacy or incidence of secondary 
malignancy have not yet been done.3 
 Recurrent or anaplastic oligodendrogliomas are treated with some combination of 
resection, radiation, and chemotherapy.  Roughly 75% of these patients respond to 
PCV,40-42 although monotherapy with temozolomide might be efficacious and better 
tolerated.43 Regardless, patients invariably relapse if chemotherapy is given without 
radiation.3  Salvage regimens include using carboplatin or high does thiotepa with stem 
cell rescue.3   
Prognosis 
The natural history of gliomas can range from slow-growing to rapidly fatal.  The 
mean survival time differs for the subtype of glioma and age of the patient.  
Oligodendroglioma WHO grade II mean survival averages 11.6 years while anaplastic 
oligodendroglioma survival averages 3.5 years.  Importantly, astrocytomas mean survival 
is only 5.9 years.2  Oligodendrogliomas tend to be progressive with a recurrence rate of 
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43%, 68% of which are a more malignant grade.2  The rate of progression from 
oligodendroglioma to anaplastic oligodendroglioma ranges from 5.0 to 6.6 years.2, 16   
Prognostic factors used to predict patient survival remains controversial as, with 
the exception of age, few factors have reproducibly been associated with survival (For 
summary, see Table B).   
However, there have been a number of prognostic factors that have shown 
promise and, while only in a limited number of studies, have been associated with patient 
outcome.  Age, tumor location, presence of neurological deficits,  presenting symptom, 
degree of surgical intervention, and ABO blood type have been correlated with outcome 
while gender has not.12  Age is one of the strongest predictors of survival with one study 
demonstrating that patients who were less than 20 years old had a median survival of 17.5 
years whereas patients over 60 years old had a median survival of 13 months.36 Another 
study demonstrated patient survival to be correlated to age with 75% of patients under 30, 
43% patients age 30-50, and only 21% of patients over 50 survive 10 years after 
diagnosis.44 The importance of age has been verified by a number of studies.15, 20, 25, 26, 45, 
46  Tumor location has been strongly associated with survival such that patients with 
frontal lobe tumors survive longer than those patients with tumors in any other location.25  
Interestingly, this location is associated with LOH on 1p/19q.  Tumors that cross the 
midline have been associated with poorer survival.46  The presence of neurological 
deficits is a negative prognostic factor; patients with deficits had a median survival of 2.5 
years whereas those without had a median survival of 11 years.46  Another study noted a 
5 year survival discrepancy such that 5% of patients with neurological deficits versus 
43% of those without were still alive.36  One study found presenting symptom to be of 
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prognostic significance such that patients who presented with seizures had better 
survival.45  Patient survival has been correlated to degree of surgical intervention with 
57% of patients with gross total resection, 48% of patients who underwent biopsy only, 
and 33% of patients with sub-total resection surviving 10 years post-operatively.44  
However, other studies have found no correlation between surgical intervention and 
survival.45  Interestingly, ABO blood type has been shown to be associated with 
differences in outcome such that patients had consistently shorter survival with blood 
type A vs. B or O.12 
Some studies have demonstrated histological grade to be associated with 
survival20, 25, 45 while others have addressed individual characteristics.  Degree of nuclear 
atypia and presence or absence of necrosis have not been associated with survival.34  One 
study noted that for patients with grade II tumors, 46% were alive after 5 years whereas 
patients with grade III tumors only 10% were alive.36  Presence of mitoses, endothelial 
hypertrophy, endothelial proliferation, and necrosis have been associated with survival 
although poorly reproducible between observers.44  The same study demonstrated the 
presence of endothelial proliferation to be independently associated with survival having 
a hazard ratio of 2.7 (95% confidence interval 1.5-4.8, p<.001) even when calculated by 
consensus scores and not individual scores.  “Endothelial hyperplasia” has been 
demonstrated to significantly correlate with survival such that median survival was 3.5 
year for patients with hyperplasia versus 11 years for patients with no hyperplasia.  
However, that study failed to associate endothelial proliferation or glomeruloid vessels 
with survival.34  Another study used vascular endothelial surface area index (VESI) as 
defined by the CD-34 immunostained endothelial area in μm2 per 1000 tumor cells as a 
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prognostic marker.  They noted patients with VESI scores of less than 15 had longer 
survival than patients whose tumors scored over 15.47   
 Mitotically active tumors are thought to be more malignant and thus have a poorer 
prognosis than inactive tumors.  Interestingly, the number of mitotic figures has such 
variability between pathologists that this marker has been shown to not predict survival in 
some studies25, 44 but does in others.20  Markers of cellular proliferation have been shown 
to have prognostic value.  Ki-67 labeling index (LI) reflects the percentage of MIB-1 
labeled cells and is a commonly used marker due to its ability to be used in paraffin-
embedded tissue and minimal technical concerns.26  It has been shown to more accurately 
reflect mitotic activity than counting mitoses44 but has to be validated within each 
individual institution.3  Disease-free survival and overall survival correlate with lower Ki-
67 labeling indices20 and Ki-67 index has been shown to have prognostic significance 
independent of patient age, tumor site, and histology.25, 26  Conversely, higher Ki-67 
labeling indices have been associated with decreased survival.15  Ki-67 labeling indices 
have also been associated with tumor grade such that in one study the mean proliferation 
rate of WHO grade II oligodendrogliomas was 7.7% versus WHO grade III tumors with 
16.9%.38  Another marker of proliferation is topoisomerase IIα, a molecular target for 
certain chemotherapeutic drugs that has been shown to have prognostic value in a variety 
of cancers.48  Higher portion of topoisomerase IIα positive cells (>3.3%) has been 
associated with higher grade tumors and higher tumor proliferation rate but not with 
gender or age.48  A lower portion of topoisomerase IIα positive cells is strongly 
associated with improved survival at 5-year follow up such that of patients with <3.3% 
nuclei positive for topoisomease IIα, 88% were alive after 5 years versus only 69% of 
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those with higher rates.38  Older means of determining mitotic activity, such as using 
antibodies to detect the presence of cyclin and proliferating cell nuclear antigen (PCNA) 
have not proven reliable.49, 50 
 Various immunohistochemical markers have been utilized with limited utility.  
Cyclooxygenase, an enzyme involved in prostaglandin synthesis, has been associated 
with survival.  COX-1a levels, a protein constitutively expressed in microglia, are 
significantly lower in low grade oligodendrogliomas and are associated with longer 
progression free and overall survival.51  Negative prognostic markers have included 
CDKN2A deletions15 and increased p53 levels.  However, other studies have failed to 
correlate p53 levels with survival.20  Patients with CDKN2A deletion or decreased p16 
expression have been shown to have significantly shorter overall survival.  Interestingly 
these deletions are inversely correlated with LOH on 1p/19q.15  High p53 levels such that 
over 75% of cells are immunoreactive is associated with reduced survival19 while other 
studies have shown no relationship.20 
Finally, in addition to its diagnostic value, tumor features on MRI can also be 
used for prognosis.  Necrosis, a histological feature known to be associated with poorer 
outcomes, may be seen as higher or lower intensity on T1 weighted imaging as well as on 
T2 weighted imaging due to paramagnetic cations and free radicals or cystic changes 
with increased water.  FLAIR imaging is an additional useful tool for determining cystic 
degeneration.5   However, the only imaging characteristic demonstrated to be 
significantly associated with outcome is T1 weighted post-gadolinium enhancement’s 
association with shorter survival15 where one study  reported a median survival difference 
of 3 versus 11 years for patients with and without contrast enhancement.34 
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Statement of hypothesis 
 We seek to better understand prognostic factors in oligodendrogliomas.  
Specifically, we will examine the potential association between age, gender, tumor grade, 
allelic status on 1p/19q and MRI features with survival.  Age, a proven prognostic factor, 
and gender, known to be independent of survival, will be used to validate our test 
population.  Tumor grade will be included due to controversy over its association with 
survival.  Allelic status will be addressed in order to confirm or refute recent studies 
associating LOH on 1p/19q with chemosensitivity and overall prolonged survival.  As 
there is an established association between 1p/19q LOH and indistinct borders on T1 
weighted pre-gadolinium MRI, this feature will be the focus of our study.  We seek to 
confirm the association between indistinct tumor borders on T1 weighted pre-gadolinium 
MR imaging and 1p/19q LOH while also determining if there is an association between 
indistinct tumor borders and survival.  This finding would suggest that MR can be used as 
a prognostic factor and determinant of therapy when allelic status of the tumor is 
unknown. 
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Methods 
 Case selection.  Cases were chosen from patients seen at the Yale Brain Tumor 
Center between 1995 and 2005 and selected based on fulfillment of all eligibility criteria.  
Demographic information including date of diagnosis, age, and gender were collected.  
Eligibility criteria included availability of original pathology, age over 16 years, pre-
operative MR imaging, and survival data.  A search of the Department of Pathology 
database revealed 260 pathology reports with a final diagnosis of “oligodendroglioma.”  
These reports were pulled and reviewed.  43 cases represented tumor recurrences and 
were therefore excluded.   74 cases had age under 16 years or lack of age data and were 
therefore excluded.  Pre-operative MRI studies were acquired from Yale-New Haven 
Hospital’s online database or original films were reviewed from outside hospitals.  50 
patients for whom imaging was not available were excluded from the study.  Survival 
information was obtained from the Yale-New Haven Hospital Tumor Registry and from 
private clinic notes.  Length of survival was calculated as the number of days from the 
date of tissue diagnosis to death or date of last follow-up.  Time of progression free 
survival could not be included as an alternative outcome as that information was not 
consistently available.  Ultimately 89 patients were included in the study, 36 of whom 
had known allelic status.   
 Pathology review.  Pathology reports were reviewed. Only those with a final 
diagnosis of oligodendroglioma or anaplastic oligodendroglioma were included.  
Histopathologic features evaluated included predominant cell type, presence of 
endothelial proliferation, presence of necrosis, and Ki-67 labeling index.  Histologic 
grade was determined by pathologist statement.  When the pathologist did not make a 
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definitive comment, tumors were designated grade III if endothelial proliferation and 
necrosis were present along with a Ki-67 labeling index over 5.0.  Genetic analysis 
reports were amended to the original path reports.  Allelic status was determined in one 
of two ways.  The allelic status of one subset was determined using PCR technology at 
Johns Hopkins University.  After the technology became available at Yale-New Haven 
Hospital, the remainder of patients underwent LOH analysis using FISH.  Studies have 
demonstrated comparable sensitivity and specificity between these two techniques. 
 Image analysis.  MRI scans were assessed by medical student HM and neuro-
oncologist JB.  Both reviewers were blinded to genetic analysis and survival information.  
Only T1-weighted pre-gadolinium, T1 weighted post-gadolinium, and T2-weighted MR 
images were consistently available.  Each T1-weighted pre-gadolinium image was 
evaluated qualitatively for distinct (see Figure 1) vs. indistinct (see Figure 2) tumor 
borders.  Tumors deemed to have “distinct borders” were noted to have sharp tumor 
edges such that the distinction between tumor and surrounding normal tissue clear.  These 
tumors also tended to also appear more hypointense and homogeneous.  Tumors deemed 
to have “indistinct borders” were noted to lack a clear transition point between tumor and 
surrounding normal tissue.  These tumors also tended to appear more heterogenous and 
isointense compared to grey matter.  T2 weighted images were not used as previous 
studies indicated T1 weighted imaging characteristics are more likely to be associated 
with genetic status.  CT scans were not consistently available to evaluate for calcium 
contents.  Intra and inter observer correlation rates were not calculated.  However, 
observationally there were few discrepancies.   
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 Statistical considerations.  Data were entered in excel spreadsheet and analyzed 
using SAS (version 9.1 SAS Institute, Cary, NC).  Two-sided chi-square tests were used 
to assess differences in death rate in gender, tumor grade, allelic status and MRI 
characteristics.  In case were the expected cells were small, Fisher's exacts tests were 
employed. Kaplan-Meier survival curves were used to calculate the estimated cumulative 
survival rate for gender, tumor grade, allelic status, and MRI characteristics.  The 
differences in the survival rate were tested by means of the two-sided log-rank test. Cox 
proportional hazard modeling was used to examine covariate effects on survival rate.  
One way ANOVA and generalized linear modeling (GLM) were used to assess the 
difference in means of surviving days for each outcome measure defined by specific 
criteria. In all analysis a two tailed alpha of < 0.05 was considered statistically 
significant. 
. 
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Results 
 89 patients were included and consisted of 43 males and 46 females.  The mean 
age at diagnosis was 43.3 years with a range of 16 to 85.  The average survival was 1573 
days with 86% of patients still alive.  Clinical, radiographic, and genetic features are 
summarized in Table C.   
 Gender, tumor grade, allelic status on 1p/19q and imaging characteristics were not 
significantly associated with survival (See Table D, E).  36 females (84%) were still alive 
while 39 males (80%) were still alive (p=.7696).  The mean survival for females was 
1193.47 days, for males 1909.89 days (p=.0765).  The Kaplan-Meier survival analysis for 
gender likewise failed to reveal a significant difference between groups (see Figure 3).  
72 patients were diagnosed with “oligodendrogliomas grade II,” 16 with 
“oligodendroglioma grade III.”  Of patients with grade II tumors, 64 (89%) were alive 
with a mean survival of 1606.69 days.  Of patients with grade III tumors, 12 (71%) were 
alive (p=.1185) with a mean survival of 1431.88 days (p=.7338).  Likewise, Kaplan-
Meier survival analysis failed to reveal a significant difference (see Figure 4).   
 36 (40%) of patients had know allelic status.  Of these, 28% harbored LOH on 1p, 
36% had LOH on 19q, 22% LOH on 1p and 19q, while 56% had intact 1p and 19q.  
Interestingly, of patients with known allelic status, only 2 patients had died making 
statistical analysis of morbidity data impossible (See Figure 5).  Mean survivals days can 
be analyzed, however they have limited utility in determining long-term survival given 
the short period of follow-up.  Patients with 1p LOH had a mean survival of 676.81 days 
while those with retained heterozygosity survived a mean of 564.08 days (p=.6871).   
Patients with 19q LOH had a mean survival of 691.93 days while those with retained 
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heterozygosity survived a mean of 539.09 days (p=.5628).  While there is a large absolute 
difference in 1p and 19q LOH survival, significant variability and imbalance within the 
data set contributed to failure to achieve statistical significance. 
 MRI characteristic analysis revealed 37% of patients had distinct borders while 
63% had indistinct borders.  24 (80%) of patients with distinct borders were still alive 
with a mean survival of 1874.97.  47 (89%) of patients with indistinct borders were still 
alive (p=.3366) with a mean survival of 1369.47 days (p=.2515).  Kaplan-Meier survival 
analysis failed to demonstrate a significant difference (see Figure 6).   
 Cox proportional hazard ratio also failed to reveal any of the potential prognostic 
factors as significant independent predictors of survival.  Age, gender, and tumor grade 
were included in the model while allelic status and imaging characteristics were not due 
to model distortion.   
 Finally, no association was found between allelic status and MR imaging 
characteristics.  Of patients with 1p LOH, 8 (80%) had indistinct borders while 2 (20%) 
had distinct borders.  Conversely, of patients with retained heterozygosity on 1p, 14 
(64%) had indistinct borders while 8 (46%) had distinct borders (p=.4399).  Of patients 
with 19q LOH, 9 (69%) had indistinct borders while 4 (31%) had distinct borders.  Of 
patients with retained heterozygosity on 19q, 13 (68%) had indistinct borders while 6 
(32% had distinct borders (p=1.000) 
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Discussion 
 New discoveries in the pathogenesis and therapeutic sensitivity of 
oligodendrogliomas represent some of the most significant progress within neuro-
oncology over the past 20 years.  The association between 1p/19q LOH and 
chemosensitivity has revolutionized therapeutic decision making.  While the use of 
1p/19q testing has become increasingly widespread for its diagnostic and therapeutic 
importance, its use remains limited to major academic institutions.  Further investigation 
of prognostic factors for oligodendrogliomas remains important as the significance of 
genetic mutations continues to unravel. 
 Our study sought both to confirm established prognostic factors and investigate 
the utility of MRI as an additional clinical prognostic factor.  A single-institution, 
retrospective study yielded a very limited number of subjects leading to difficulties with 
statistical power to detect significant differences.  This major limitation is manifested by 
our data departing significantly from previous literature on several key, fundamental 
points.  First, previous descriptive studies have established the expected male-to-female 
gender ratio to be as much as 3.0.6  Our studies revealed a departure from this expectation 
with an almost equal distribution between the genders.  This simple inconsistency may 
reflect the potential biases in our sample due to the relatively small number of cases.  We 
did find gender to be independent of survival as previous studies have shown.  In fact, the 
Kaplan-Meier survival curve for females and males follow almost the exact same path 
confirming that males and females with olidodendrogliomas do equally well.   
 The mean age at diagnosis for our patients was 43.3 years.  In previous studies, 
age has persistently proven the strongest prognostic factor in oligodendrogliomas yet 
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failed to predict survival in our study.  Of note, most previous studies have approached 
the question of age by grouping patients into categories such as those patients under 30, 
aged 30-50, and those over 50 years.44  We took a different approach and used age as a 
continuum in order to decipher if there is a linear, and not just categorical, relationship 
between age and mean survival.  However, we found neither absolute survival nor mean 
survival days to be associated with age at diagnosis.  Thus, it may not be correct to 
assume older age has a linear relationship to worsening prognosis.  Clinically, it may be 
more useful to risk stratify patients into age categories such that those over 50 years old 
having expected shorter survival than those younger but not differentiate between two 
patients who are both over 50 years.  However, again our study is limited by statistical 
power secondary to small sample size. 
 While multiple studies have correlated tumor grade to survival, others have found 
no such correlation but relied instead on individual aspects that contribute to grading.  
While advanced tumor grade should be, a priori, associated with poorer survival, this has 
been inconsistently demonstrated in the literature.  Our study found no association 
between tumor grade and survival.  Although the Kaplan-Meier survival curve looks 
promising, it did not achieve statistical significance.  Factors influenced by 
histopathological grade such as degree of surgical resection and subsequent treatment 
decisions may play a stronger role than the aggressiveness of the tumor histopathology 
itself.  We did not address individual characteristics such as Ki-67 labeling index, the 
presence of necrosis, or endothelial hyperplasia.  Addressing these characteristics instead 
of the tumor grade may prove more revealing. 
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 The frequency of 1p/19q LOH in oligodendrogliomas ranges from LOH on 1p in 
40-92% averaging 83%27, LOH on 19q in 50-80% averaging 66%.8, 27  Our study found 
that of the small number of patients with known allelic status, only 28% had LOH on 1p 
and 36% had LOH on 19q.  This frequency more closely approximates the earlier, 
smaller studies whereas it is the more recent, larger scale studies that reveal higher 
frequencies.  There are many potential reasons for the disparity.  First, we had a relatively 
small sample size with only 36 patients having known allelic status.  This small number 
may lead to a number of potential selection biases.  For example, prior to the widespread 
acceptance of the importance of determining allelic status, genetic testing may have been 
done only in those patients with questionable histopathology and not on those patients 
with clear oligodendrogliomas.  Additionally, two different tests were used to determine 
allelic status: some patients were tested using PCR at an outside institution while others 
were tested using FISH in our own Department of Pathology.  While there are no known 
disparities of significance in the sensitivity and specificity of these two techniques, there 
is the possibility that this inconsistency biased the results.  Even within the small sample 
size of patients with known allelic status, the rarity of LOH on 1p/19q further 
compromised our statistical power.  In addition, of those patients with know allelic status, 
only 2 patients had expired.  Previous studies have addressed populations with less than 
50% of patients still alive.  The longevity of these patients made determining an 
association between 1p/19q LOH and absolute survival impossible.  Likewise, addressing 
mean survival days was also challenging as these numbers reflect time since diagnosis 
and not necessarily length of survival given the short follow-up time.  Longer follow-up 
times are needed to confirm the association between 1p/19q LOH and longer survival. 
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 The major focus of our study was to address MRI characteristics as a possible 
independent prognostic factor as previous studies have demonstrated an association 
between certain features and 1p/19q LOH.  Specifically, studies have found that T1 pre-
gadolinium indistinct tumor borders, presence of susceptibility effect, heterogeneous 
signal intensity, and frontal lobe location are all associated with LOH on 1p/19q.7, 32 
Establishing the association of any of these imaging features with improved outcome 
would benefit areas where genetic testing has not yet come into widespread use and allow 
the clinician to offer the patient prognostic information even before a tissue diagnosis is 
made.  We chose to address T1 pre-gadolinium tumor border characteristics as T1-
weighted images are most consistently available to clinicians.  In our study, tumor 
imaging on T1 weighted, pre-gadolinium MRI was classified as having either a “distinct 
border” or an “indistinct border.” We found no association between border characteristics 
on MRI and 1p/19q status or survival.  While this is an unexpected result given previous 
studies demonstrating the association between this imaging feature and 1p/19q status, 
there are multiple reasons why detecting a difference between these two groups proved 
challenging.  First, we found that the difference between distinct and indistinct borders 
was not always clear.  Tumors located in the temporal lobe were particularly challenging 
due to the size of sulci.  When a tumor border abutted a sulcus, the border appeared 
deceptively sharp in that cut. Tumors directly adjacent to ventricles could also have 
deceptively distinct borders.  Each of these biases was minimized by analyzing the tumor 
characteristics in both coronal and sagittal cuts.  Finally, oligodendrogliomas are 
notoriously heterogeneous with multiple areas of distinct and indistinct borders within the 
same tumor.  Given these discrepancies, additional characteristics occasionally aided in 
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determining if the tumor should be designated as having distinct or indistinct borders.  
While these characteristics have not been addressed in previous studies, they proved 
subjectively useful in our study.  We found that tumors with indistinct borders tended to 
be more isointense with respect to gray matter while tumors with distinct borders tended 
to appear hypointense.  Tumors with indistinct borders also appeared more heterogeneous 
while tumors with distinct borders were frequently homogeneous.  These challenges 
would suggest that while MR characteristics can not be used as a prognostic factor, we 
hesitate to definitively rest on these findings.  Our hesitation comes from our limited 
power to detect a difference and the inconsistencies shown in other factors we addressed.  
Further study addressing other imaging characteristics and developing additional criteria 
to distinguish between distinct and indistinct borders may prove useful.  If reliably 
available, cystic changes on FLAIR images may also be a useful radiographic prognostic 
marker.5  The presence of calcium, traditionally considered an ominous histopathologic 
sign, can only be reliably detected through MRI using gradient echo images, a technique 
that is not yet standard on all MRIs.  If these images could be obtained reliably, their 
prognostic value could prove interesting.      
 Our data set contains multiple factors that limited our ability to significantly 
detect the importance of various prognostic factors, including confirming the importance 
of 1p/19q LOH and determining the significance of MRI characteristics.  Having only a 
small number of patients leads to limited statistical power.  This small sample size was 
due to both the relative rarity of the tumor and the limitations in our ability to obtain 
pathologic data, pre-operative imaging, allelic status, and survival information on many 
of the patients.  Sample size remained small due to the limited clinical use of 1p/19q data 
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as this test has been used clinically for less than 5 years.  Another interesting point is the 
survival of the patients.  Where other studies have considered samples where 
approximately 50% of patients had died,44, 46 our sample had only 15% of patients 
expired.  This may be due to the relatively short amount of follow-up time.  Where our 
mean follow-up time was 1,573 days (approximately 52 months), other studies have 
averaged 6.646 to 8.7 years.44   This observation proves important in light of the average 
survival of 11.6 years for patients with Grade II tumors.2 
 There are numerous potential prognostic factors that we did not directly address in 
this study that should be re-examined in light of new data on allelic status.  Demonstrated 
prognostic factors such as presenting symptom, presence of neurological deficits at 
presentation, frontal lobe location, blood type, and Ki-67 labeling indices require further 
study and were unfortunately largely unavailable for the current project.  Likewise, 
growth across the midline has been associated with poorer survival.46  In other studies, 
this growth pattern has been associated with the presence of 1p/19q LOH which would 
thus indicate increased chemosensitivity and improved survival.7  This discrepancy 
requires further investigation.  Finally, PET technology has great potential as a prognostic 
factor that has not yet been studied.  While this study attempted to further investigate the 
role of prognostic factors in oligodendrogliomas, further work needs to be done in light 
of the dramatic molecular advances in tumor diagnosis and therapy. 
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Appendix 
 
Table A WHO Classification of Gliomas1
Astrocytic tumors Ependymal tumors 
Diffuse astrocytoma Ependymoma 
       Fibrillary astrocytoma        Cellular 
       Protoplasmic astrocytoma        Papillary 
       Gemistocytic astrocytoma        Clear cell 
Anaplastic astrocytoma        Tanycytic 
Glioblastoma Anaplastic ependymoma 
       Giant cell glioblastoma Myxopapillary ependymoma 
       Gliosarcoma Subependymoma 
Pilocytic astrocytoma  
Pleomorphic xanthroastrocytoma  
Subependymal giant cell astrocytoma  
Oligodendroglial tumors  
Oligodendroglioma  
Anaplastic oligodendroglioma  
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Table B Prognostic factors in oligodendrogliomas 
Unfavorable Favorable Not demonstrated 
Older age, especially  >50 
years old 
Younger age, especially 
<30 years old 
 
  Gender 
Contrast enhancement   
Tumor crosses the midline Frontal location  
Neurological deficits at 
diagnosis 
No Neurological deficits at 
diagnosis 
 
 Presenting symptom 
seizures 
 
Subtotal resection Gross total resection  
WHO Grade III WHO Grade II  
Vascular changes No vascular changes  
Higher Ki-67 index, 
especially  
Lower Ki-67 index, 
especially  
 
10q deletion, 8q gain Chromosome 1p and/or 19q 
deletion 
 
P16/CDKN2A deletion  EGFr expression 
Increased p53   
Type A Blood   
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Table C     Clinical, radiographic, and genetic features 
Total number of patients 89  
          Patients without genetic studies 53 (60%) 
          Patients with genetic studies 36 (40%) 
Mean age at diagnosis (years) 43.3  (16-85) 
M/F (n) 43/45  
Tumor grade   
         Grade II Tumors 72 (82%) 
         Grade III Tumors 16 (18%) 
Imaging   
         Tumor with distinct border on T1 MRI 30 (37%) 
         Tumor with indistinct border on T1 MRI 51 (63%) 
Genetics   
         Patients with known allelic status 36  
         1p LOH 10  28% 
         19q LOH 13  36% 
         1p and 19q LOH 8 22% 
         1p and 19q intact 20 56% 
Survival   
         Alive 76 (86%) 
         Dead 12  (14%) 
         Mean survival (days) 1573 (30-8897) 
a LOH, loss of heterozygosity 
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Table D Statistical analysis of morbidity results 
Variable Alive Dead P-value* 
Gender   .7696 
     F 36 7  
     M 39 6  
Tumor grade   .1185 
     WHO Grade II 64 8  
     WHO Grade III 12 5  
MRI   .3366 
     Distinct border 24 6  
     Indistinct border 47 6  
Allelic status on 1p   .5238 
     1p LOH 10 1  
     1p heterozygosity 24 1  
Allelic status on 19q   .5111 
     19q LOH 14 0  
     19q heterozygosity 20 2  
* Fisher’s exact test 
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Table E Statistical analysis of mean survival days 
Variable Mean survival SD P-value* 
Gender   .0765 
     Male 1909.89 2361.35 (30-8897)  
     Female 1193.47 1160.55 (186-4867)  
Tumor grade   .7338 
     WHO Grade II 1606.69 1825.51 (32-8897)  
     WHO Grade III 1431.88 2202.21 (30-7333)  
MRI   .2515 
     Distinct border 1874.97 2246.33 (32-8733)  
     Indistinct border 1369.47 1720.21 (30-8897)  
Allelic status on 1p   .6871 
     1p LOH 676.81 874.13 (41-2523)  
     1p heterozygosity 564.08 717.51 (30-3545)  
Allelic status on 19q   .5628 
     19q LOH 691.93 796.03 (41-2523)  
     19q heterozygosity 539.09 745.03 (30-3545)  
* Generalized linear model 
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Table F Cox proportional Hazard Analysis 
Variable Hazard ratio Pr > Chi-square 
Age 1.012 0.4920 
Gender 0.930 0.9088 
Tumor grade 1.897 0.2977 
 
Table G Statistical analysis of relationship between allelic status and imaging  
  characteristics 
 
Variable Distinct borders Indistinct Borders P-value* 
Allelic status: 1p   .4399 
     LOH 2 8  
     Heterozygous 8 14  
Allelic status: 19q   1.000 
     LOH 4 9  
     Heterozygous 6 13  
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Table H Abbreviations 
 
1p Short arm of chromosome 1 
19q Long arm of chromosome 19 
1p/19q LOH LOH on 1p and/or 19q  
AAD14 Gene encoding AAD14 protein 
CAMTA1 Calmodulin binding transcription activator 1 
CDK4 Cyclin-dependent kinase 4 
CDKN1A Cyclin-dependent kinase inhibitor 1 
CDKN2A/p14ARF Cyclin-dependent kinase inhibitor 2A and encoded protein p14 or 
p16 
COX, COX-1a Cyclooxygenase, Cyclooxygenase subtype 1a 
CT Computer tomography 
DNT Dysembryoplastic neuroepithelial tumor 
EGFR Endothelial growth factor receptor 
FISH Fluorescence in situ hybridization 
GABA-BR1A GABA-B receptor 1A subunit 
GalC Galactocerebroside 
GBM Glioblastoma multiforme 
GFAP Glial fibrillary acidic protein 
Histone H4 Histone subtype H4 
IFI-56K Interferon-induced 56-kDa protein 
ITGB4 Integrin beta 4 
JNK2, JNK3 A2 c-jun N-terminal kinase 2, 3 alpha 2 
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Jun-D Gene encoding protein Jun-D 
Ki-67 Nuclear protein marker expressed only when cells are actively 
dividing 
LOH Loss of heterozygosity 
MIB-1 Ab Antibody marker of Ki-67 
MRI Magnetic Resonance Imaging 
Olig2 Oligodendroglial lineage gene number two 
P190RhoGAP RhoA-specific GAP 
PCDH43 Protocadherin 43 precursor 
PCNA Proliferating cell nuclear antigen 
PCR Polymerase chain reaction 
RB1 Retinoblastoma gene 1 
Rho7 Gene encoding protein Rho7 
RhoC Gene encoding for protein RhoC 
TDGF1 Teratocarcinoma-derived growth factor 1 
TGF-β Transforming growth factor-beta 
WHO World Health Organization 
YLK-40 A secreted glycoprotein 
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Figure 1 48 year old man with tissue diagnosis of oligodendroglioma with  
  retained heterozygosity on 1p and 19q demonstrating distinct borders  
  on axial T1 pre-gadolinium magnetic resonance imaging. 
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Figure 2 46 year old man with tissue diagnosis of oligodendroglioma with loss  
  of heterozygosity on 1p and 19q demonstrating indistinct borders on  
  axial T1 pre-gadolinium magnetic resonance imaging. 
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Figure 3 Kaplan-Meier survival analysis for gender.  The two groups did not  
  have significantly different survival.   
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Figure 4 Kaplan-Meier survival analysis for tumor grade.  The two groups did  
  not have significantly different survival. 
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Figure 5 Kaplan-Meier survival analysis for allelic status on chromosome 1p.   
  The two groups did not have significantly different survival. 
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Figure 6 Kaplan-Meier survival analysis for tumor border characteristics on  
  T1 pre-gadolinium MRI.  The two groups did not have significantly  
  different survival. 
 
 
 
 
 
